Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Verve Therapeutics (VERV) to $15 from $14 and keeps a Buy rating on ...

Vertex Pharmaceuticals exits liver disease gene editing program with Verve Therapeutics. Verve continues work on a separate ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose ...

EXCLUSIVE: Verve Ventures, Verve’s film financing and sales division, has boarded Good Boy to represent worldwide rights, ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited ...

Verve Therapeutics (VERV) delivered earnings and revenue surprises of 19.44% and 90.39%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

AI, human and cultural understanding business Verve has named Peter Latham as director as part of 11 promotions at the ...

EXCLUSIVE: Verve has welcomed agent Barrett Bischoff to its Talent team and promoted Lacey Hunsucker to Talent Agent. In his ...

Pharoah Sanders’ 'Love In Us All' and Bennie Maupin’s 'Slow Traffic To The Right' will both receive new vinyl pressings via Verve By Request.